Unknown

Dataset Information

0

N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.


ABSTRACT:

Background

A considerable body of human and animal experimental evidence links monoaminergic systems and cognition. Monoamine oxidase inhibitors (MAOIs), being able to enhance monoaminergic transmission and having neuroprotective properties, might represent a promising therapeutic strategy in cognitive impairment in Alzheimer's disease (AD) and other dementias.

Methods

The MAO-A and MAO-B inhibition profile of N-(furan-2-ylmethyl)-N-prop-2-yn-1-amine derivates (compounds 1-3) were evaluated by fluorimetric method and their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties estimated. The effects of the selected compound 1, N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA), were evaluated on the basic synaptic transmission, long-term potentiation (LTP), and excitability in the dentate gyrus (DG) of the hippocampus of anesthetized rats.

Results

F2MPA is a partially reversible inhibitor of hMAO-B, with moderate to good ADMET properties and drug-likeness. Intraperitoneal administration of 1 mg/kg F2MPA greatly enhanced basic synaptic transmission, induced LTP, and potentiated electrically induced LTP in the dentate gyrus. Moreover, F2MPA did not modify seizure threshold of pilocarpine-induced convulsion in CD1 mice.

Conclusion

Our findings suggest that, the MAO-B inhibitor, F2MPA improves DG synaptic transmission without triggering pathological hyperexcitability. Therefore, F2MPA shows promise as a potential cognition-enhancing therapeutic drug.

SUBMITTER: Di Giovanni G 

PROVIDER: S-EPMC6493173 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.

Di Giovanni Giuseppe G   García Isela I   Colangeli Roberto R   Pierucci Massimo M   Rivadulla Marcos L ML   Soriano Elena E   Chioua Mourad M   Della Corte Laura L   Yáñez Matilde M   De Deurwaerdère Philippe P   Fall Yagamare Y   Marco-Contelles José J  

CNS neuroscience & therapeutics 20140521 7


<h4>Background</h4>A considerable body of human and animal experimental evidence links monoaminergic systems and cognition. Monoamine oxidase inhibitors (MAOIs), being able to enhance monoaminergic transmission and having neuroprotective properties, might represent a promising therapeutic strategy in cognitive impairment in Alzheimer's disease (AD) and other dementias.<h4>Methods</h4>The MAO-A and MAO-B inhibition profile of N-(furan-2-ylmethyl)-N-prop-2-yn-1-amine derivates (compounds 1-3) were  ...[more]

Similar Datasets

| S-EPMC2959693 | biostudies-literature
| S-EPMC3998425 | biostudies-literature
| S-EPMC7827014 | biostudies-literature
| S-EPMC2977485 | biostudies-literature
| S-EPMC2959671 | biostudies-literature
| S-EPMC2960820 | biostudies-other
| S-EPMC3201401 | biostudies-literature
| S-EPMC5018869 | biostudies-other
| S-EPMC3515244 | biostudies-other
| S-EPMC3120489 | biostudies-literature